Neutralising Antibodies to Interferon- in the Treatment of Multiple Sclerosis: Cause for Concern?

ISSN： 1172-7047

Source： CNS Drugs, Vol.11, Iss.3, 1999-03, pp. : 225-243

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Off-Label Use of Atypical Antipsychotics: Cause for Concern?

By McKean Andrew

CNS Drugs, Vol. 26, Iss. 5, 2012-05 ,pp. : 383-390

Adis International

Access to resources Recommend Favorite

Safety of Agents Used to Prevent Mother-to-Child Transmission of HIV: Is There Any Cause for Concern?

By Thorne Claire Newell Marie-Louise

Drug Safety, Vol. 30, Iss. 3, 2007-01 ,pp. : 203-213

Adis International

Access to resources Recommend Favorite

Hypotonic-Hyporesponsive Episodes Following Pertussis Vaccination: A Cause for Concern?

By Gold M.S.

Drug Safety, Vol. 25, Iss. 2, 2002-01 ,pp. : 85-90

Adis International

Access to resources Recommend Favorite

Interferon-Beta in the Treatment of Multiple Sclerosis: Do Clinical Data Support the Existence of a Ceiling Effect?

By Clanet M.

Clinical Drug Investigation, Vol. 21, Iss. 4, 2001-04 ,pp. : 307-318

Adis International

Access to resources Recommend Favorite

Inhaled corticosteroid-associated adrenal crisis of concern?

Inpharma, Vol. 1, Iss. 1368, 2002-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite